SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

CESSATION OF DIRECTORSHIP

The board (the "**Board**") of directors (the "**Directors**") of Sunho Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") announces that with effect from July 22, 2026, Mr. Fan Rongkui ("**Mr. Fan**") will cease to be a non-executive Director upon expiration of his term of office under the service contract entered into between the Company and Mr. Fan (the "**Director's Service Contract**").

Pursuant to the Director's Service Contract, the term of office of Mr. Fan will expire on July 22, 2026, and the Director's Service Contract will not be renewed. Accordingly, Mr. Fan will cease to be a Director with effect from July 22, 2026. Mr. Fan has confirmed that, based on the information currently available and as of the date of this announcement, he has no disagreement with the Board or any member thereof and that there are no matters in relation to his cessation of directorship that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Mr. Fan hereby states that the Company is currently conducting an independent investigation into certain matters, the results of which have not yet been released, and that this confirmation is based on the information available to him as a Director as of the date of this announcement. Such cessation will not cause the number of Board members to fall below the minimum number required under the articles of association of the Company (the "**Articles of Association**") and the composition of the Board will fully comply with all relevant requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association.

The Board would like to take this opportunity to express its gratitude to Mr. Fan for his efforts and valuable contributions to the Group during his tenure of office.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the Company's annual results for the year ended December 31, 2025.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders and potential investors of the Company are advised to seek advice from professional or financial advisors.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, July 21, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.